Physician profile
Heather Cook
NPI 1467602219
$5,639.54
in general payments reported to CMS, 2019-2025
22 companies · $555 in 2025
The $555 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,458 · 2022: $1,049 · 2023: $1,453 · 2024: $1,124 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,132.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,132.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,761.54 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $472.19 | 2021-2025 | |
| Lilly USA, LLC | $460.87 | 2021-2025 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $443.28 | 2021-2025 | Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $360.18 | 2021-2024 | Trelegy Ellipta, Bexsero, Arexvy |
| Merck Sharp & Dohme LLC | $318.46 | 2021-2023 | Verquvo, Belsomra, Lagevrio |
| Abbott Laboratories | $278.01 | 2021-2025 | Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.51 | 2021-2025 | Jardiance, Tradjenta, Ofev |
| Amgen INC. | $247.20 | 2021-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $189.93 | 2022-2025 | Xifaxan |
| Mylan Specialty L.P. | $165.51 | 2021-2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $161.89 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $103.75 | 2021-2023 | |
| Exact Sciences Corporation | $101.63 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $91.05 | 2021-2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $68.22 | 2023-2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $50.53 | 2021-2022 | |
| Amarin Pharma, INC. | $34.24 | 2021 | |
| Corium, LLC | $29.73 | 2023 | Adlarity |
| Idorsia Pharmaceuticals US INC | $18.38 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $16.39 | 2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $16.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.